Table 2.
Saline (n = 10) | Fluoxetine (n = 12) | |
---|---|---|
Activity | ||
cPLA2 (pmol/min/mg protein) | 5.42 ± 0.41 | 5.70 ± 0.28 |
sPLA2 (nmol/min/mg protein) | 104.4 ± 7.9 (n = 9) | 123.8 ± 11.6 |
iPLA2 (pmol/min/mg protein) | 47.1 ± 4.5 (n = 9) | 62.0 ± 2.1**(+31%) |
Protein (%, fluoxetine/saline) | ||
iPLA2-VIA | 100.0 ± 15.6 (n = 8) | 108.3 ± 14.4 |
COX-1 (69 kDa) | 100.0 ± 12.7 | 105.6 ± 17.6 |
COX-2 (69 kDa) | 100.0 ± 15.9 (n = 8) | 102.5 ± 12.3 |
5-LOX (78 kDa) | 100.0 ± 13.5 | 104.5 ± 9.2 |
12-LOX (75 kDa) | 100.0 ± 12.3 | 101.9 ± 6.9 |
15-LOX (79 kDa) | 100.0 ± 8.6 | 93.7 ± 6.9 |
mPGES (33 kDa) | 100.0 ± 10.7 (n = 9) | 105.45 ± 6.9 |
CYP2C9 (59 kDa) | 100.0 ± 8.1 | 79.9 ± 7.1 |
CYP4A (50-52-54 kDa) | 100.0 ± 20.0 | 25.8 ± 13.3**(−74%) |
Values are mean ± SEM.
P < 0.01, unpaired t-test